Proof-of-concept Randomized, Double-blind, Phase IIa Study to Show Feasibility, Validate Assays and Approaches, and Explore Dosing and Safety of Belimumab in Pulmonary Emphysema Patients
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
Price : $35 *
At a glance
- Drugs Belimumab (Primary)
- Indications Emphysema
- Focus Pharmacodynamics; Proof of concept
- Acronyms BOTEGA
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.